Global Hospital-Treated Gram-Negative Infections Market Analysis and Value Forec

Posted by Rashi Pande on December 17th, 2019

Market Analysis: Global Hospital-Treated Gram-Negative Infections Market

Global hospital-treated gram-negative infections market is expected to register a substantial CAGR in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. This rise in market value can be attributed to the continuous research and development of various pharmaceutical organizations.

Key Market Competitors:

Few of the major competitors currently working in the global hospital-treated gram-negative infections market are Merck & Co., Inc.; Pfizer Inc.; Lupin Pharmaceuticals, Inc.; Istituto Lusofarmaco D’Italia S.p.A.; Adelco; Achaogen, Inc.; ALLERGAN; MELINTA THERAPEUTICS, INC.; Polyphor Ltd.; Shionogi Inc.; Tetraphase Pharmaceuticals; Spero Therapeutics; AiCuris GmbH & Co. KG; Allecra Therapeutics; SUMMIT THERAPEUTICS PLC; Curza; Boston Pharmaceuticals and Nabriva Therapeutics plc among others.

Market Definition: Global Hospital-Treated Gram-Negative Infections Market

Hospital-treated gram-negative infections are microbial infections caused by different pathogens interacting with the patient’s bloodstream through wounds, surgical sites and other areas in a healthcare setting. These infections are caused by various pathogens with the most common, “klebsiella”, “E.coli”, “Acinetobacter” and various others.

Patients suffering from gram negative infections are known to have high fever, lack of appetite, nausea and in some extreme cases even seizures. Their treatment and removal is achieved with the help of combination of different therapeutics and systems inclusive of regular controlled dosage of anti-microbials with anti-biotics.

Market Drivers

  • Increasing rate and prevalence of antibiotic resistance is expected to boost the growth of the market
  • Lack of effectiveness in treating of these anti-microbial infections with the help of traditional therapeutics is expected to boost the growth of the market
  • Growing mortality rate caused by anti-microbial resistance is giving rise to better therapeutic solutions; this factor is expected to drive the growth of the market

Market Restraints

  • Lack in the availability of anti-microbial agents in the form of pharmaceuticals or drug pipeline for the treatment of gram-negative infections; this factor is expected to restrict the growth of the market
  • Significant numbers of resistance and challenges facing the companies and pharmaceuticals regarding the development of treatment solutions; this factor is expected to restrict the growth of the market

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hospital-treated-gram-negative-infections-market

Segmentation: Global Hospital-Treated Gram-Negative Infections Market

By Therapy

  • Cephalosporin, Aminoglycoside
  • Ampicillin/Sulbactam, Carbapenem, Colistin or Rifampin
  • Aminoglycoside, Carbapenem, Colistin, Fosfomycin, Rifampin, or Tigecycline
  • Ceftolozane/Tazobactam
  • Ceftazidime/Avibactam
  • Others

By Indication

  • NP
  • cSSSIs/SSIs
  • BSIs
  • cIAIs
  • UTIs

By Pathogen Type

  • Klebsiella
  • Acinetobacter
  • Coli
  • Cepacia
  • Pseudomonas
  • Serratia
  • Enterobacter
  • Others

By Application

  • Hospitals
  • Labs

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • Italy
    • U.K.
    • France
    • Spain
    • Netherlands
    • Belgium
    • Switzerland
    • Turkey
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Singapore
    • Malaysia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Rest of South America
  • Middle East and Africa
    • South Africa
    • Rest of Middle East and Africa

Key Developments in the Market:

  • In June 2019, MELINTA THERAPEUTICS, INC. announced that the US FDA had accepted the company’s supplemental NDA (sNDA) for “BAXDELA (delafloxacin)” for priority review. The application will expand the current indication application for adults with community-acquired bacterial pneumonia (CABP). This approval is based on positive results out of Phase III study
  • In October 2018, Novartis AG announced that they had agreed with Boston Pharmaceuticals for the development of anti-infective drug candidates included in “Novartis Infectious Diseases” portfolio. These candidates will be designed for treatment of anti-biotic resistance such as “gram-negative infections”. This agreement will provide Boston Pharmaceuticals worldwide rights, wherein Novartis will receive financial payments upfront as well as in royalties and milestone achievements

Competitive Analysis:

Global hospital-treated gram-negative infections market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of hospital-treated gram-negative infections market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Like it? Share it!


Rashi Pande

About the Author

Rashi Pande
Joined: November 7th, 2019
Articles Posted: 141

More by this author